BioSpace News Archive

Irritable or Inflammatory bowel disease (IBD) is a chronic disease, which is used to describe disorders that involve chronic inflammation of the digestive tract.

Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that AstraZeneca has exercised its first license option for an Invir.IO™ oncolytic virus developed from their on-going OV collaboration.

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former CEO of Celgene Corporation, Mark Alles, to its Board of Directors effective January 1, 2022.

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), today announced that the U.S. Food and Drug Administration (FDA) acknowledged that Verrica’s resubmitted New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) was complete and assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2022.

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), today announced that the first patients have been enrolled in the Phase 1 study of PF614-MPARTM, the first product utilizing the Company’s MPARTM platform designed to reduce opioid overdose.

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced that it has terminated the Stock Purchase Agreement that was executed on August 30, 2020.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), today announced that it has achieved full enrollment in its NAV3-35 Phase 2b clinical study titled “Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging with Tc99m Tilmanocept.”

PURE Bioscience, Inc., creator of the patented non-toxic silver dihydrogen citrate antimicrobial, reported financial results for the fiscal first quarter ended October 31, 2021.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), today reported business and financial results for the fiscal full year ended September 30, 2021.